Posters and Presentations
Tipifarnib
Final Results from KO-TIP-002 a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT02464228)
ASH 2021 Presentation
Antitumor activity of Tipifarnib and PI3K Pathway inhibitors in HRAS-associated HNSCC
AACR-NCI-EORTC 2021 Presentation
AACR-NCI-EORTC 2021 Poster
Final results of a phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
ESMO 2021 Poster
The AIM-HN Study: A registrational-directed study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations
ASCO 2021 Poster
Tipifarnib is Highly Active in Combination with Alpelisib in Models of HRAS/PI3K-dysregulated HNSCC
EORTC-NCI-AACR 2020 Poster
Preliminary Results From an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) and Other Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPNS)
EHA 2020 Poster
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL): Preliminary Results from an Open-Label, Phase 2 Study
EHA 2020 Poster
Preliminary Activity of Tipifarnib in Tumors of the Head & Neck, Salivary Gland, and Urothelial Tract With HRAS Mutations
ASCO 2020 Presentation
The AIM-HN and SEQ-HN Study: A Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
ASCO 2020 Poster
Tipifarnib, a Farnesyltransferase Inhibitor, for Metastatic Urothelial Carcinoma Harboring HRAS Mutations
ASCO 2020 Poster
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
ASH 2019 Presentation
Preliminary Results From a Phase 2 Trial of Tipifarnib in Head and Neck Squamous Cell Carcinomas (HNSCCS) With HRAS Mutations
AACR-NCI-EORTC 2019 Presentation
AACR-NCI-EORTC 2019 Poster
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
ICML 2019 Presentation
KIR3DL2 Mutation May Define a High Rate of Response of Aitl to Tipifarnib
ICML 2019 Poster
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
EHA 2019 Presentation
CXCL12 and CXCR3 May Identify Complete Response in Acute Myeloid Leukemia Patients Treated With Tipifarnib
EHA 2019 Poster
Mechanism of Action of the Farnesyltransferase Inhibitor Tipifarnib and its Potential Clinical Applications
AACR 2019 Poster
Patient Reported Abdominal Pain as a Surrogate of the Clinical Benefit of Tipifarnib in Pancreatic Cancer Patients
ASCO GI 2019 Poster
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
ASH 2018 Poster
Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor cell lines
ASH 2018 Poster
Tipifarnib is Highly Active in HRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Models
EORTC-NCI-AACR 2018 Poster
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Squamous Cell Carcinomas (SCCS) With HRAS Mutations
ESMO 2018 Presentation
Tipifarnib is Highly Active in HRAS-mutant Lung Squamous Cell Carcinoma Tumor Models
AACR 2018 Poster
Pre-clinical Activity of Tipifarnib in Cutaneous T-cell Lymphoma
AACR 2018 Poster
Preliminary Results from a Phase 2 Trial of Tipifarnib in HRAS mutant Head & Neck Squamous Cell Carcinomas (HNSCC)
H&N 2018 Poster
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes
ASH 2017 Poster
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma
ASH 2017 Poster
Preliminary Results From an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)
ASH 2017 Poster
Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation
ASH 2017 Poster
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations.
AACR-NCI-EORTC 2017 Presentation
Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations.
AACR-NCI-EORTC 2017 Poster
Preliminary Results From an Open-Label, Phase II Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma.
EHA 2017 Poster
Preliminary Results From an Open-Label, Phase II Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma.
ICML 2017 Poster
Tipifarnib is Highly Active in HRAS-mutant SCCHN Tumor Models.
AACR Head and Neck 2017 Poster
Preliminary Evidence of Clinical Activity With Tipifarnib in Squamous Cell Carcinomas of the Head & Neck (SCCHN) With Hras Mutations.
15th International Congress on Targeted Anticancer Therapies (TAT 2017) Presentation
Targeting the RAS-ERK Pathway.
9th European Scientific Oncology Conference (ESOC-9) Presentation
KO-539 / Menin
Clinical-Stage Menin Inhibitor KO-539 is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A/MLL-r and NPM1-Mutant AML Models.
ASH 2021 Poster
Preliminary Phase 1/2A Data From the KOMET-001 First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
ASH 2020 Presentation
ASH 2020 KOMET-001 Preliminary Data Video
A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias and NPM1/DNMT3A-mutant AML.
AACR-EORTC-NCI 2017 Poster
A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias.
AACR 2017 Poster
Discovery of Novel Menin-MLL Small Molecule Inhibitors That Display High Potency and Selectivity in Vitro and in Vivo.
EORTC 2016 Poster
Publications
Tipifarnib
Malik, et al. CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. Cancers. (December 2021)
Publication
Kessler, et al. Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas. Cancers. (October 2021)
Publication
Ho, et al. Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations. Journal of Clinical Oncology. (March 2021)
Publication
Gilardi, et al. Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 10.1158/1535-7163.MCT-19-0958 (July 2020)
Publication
Hanna, et al. Tipifarnib in Recurrent, Metastatic HRAS‐mutant Salivary Gland Cancer. Cancer, 10.1002/cncr.33036 (June 2020)
Publication
Cox, et al. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin. Cancer Res, 21(8), 1819-1827 (April 2015)
Publication
Chen, et al. Transformation by HRAS(g12v) Is Consistently Associated With Mutant Allele Copy Gains and Is Reversed by Farnesyl Transferase Inhibition. Oncogene, 33(47):5442-9 (November 2014)
Publication
Berndt, et al. Targeting Protein Prenylation for Cancer Therapy. Nature Reviews Cancer 11, 775-791 (November 2011)
Publication
Witzig, et al. Multi-Institutional Phase 2 Study of the Farnesyltransferase Inhibitor Tipifarnib (r115777) in Patients With Relapsed and Refractory Lymphomas. Blood.; 118(18):4882-9 (November 2011)
Publication
Fenaux, et al. A Multicenter Phase 2 Study of the Farnesyltransferase Inhibitor Tipifarnib in Intermediate to High-Risk Myelodysplastic Syndrome. Blood. 109(10):4158-63 (May 2007)
Publication
KO-539 / Menin
Kantarjian et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal. 11(41):1-25 (February 2021)
Publication
Miao, et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML with activating FLT3 mutations. Blood. 136(25):2958-2963 (December 2020)
Publication
Klossowski, et al. Menin Inhibitor MI-3454 Induces Remission in MLL1-Rearranged and NPM1-Mutated Models of Leukemia. J Clin Invest. 130(2):981-997 (February 2020)
Publication
Borkin, et al. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia in Vivo. Cancer Cell. 27 (4):589-602 (April 2015)
Publication